Integragen Stock

Integragen Net Margin

The Net Profit Margin of Integragen (ALINT.PA) as of Jul 28, 2026 is -53.06 %. In the previous year, Net Profit Margin was -2.94 % — a change of 1,702.72% (lower).

Net Margin

-53.06 %

YoY

1,702.72%

Last updated:

Net Profit Margin of Integragen is 2026 -53.06 % . Net Profit Margin of Integragen was 2025 -2.94 % . It decreases by 1,702.72% lower compared to the previous year.

Integragen's net margin stands at -53.1%, down from 0.1% several years earlier.

Access this data via the Eulerpool API

Integragen Stock analysis

What does Integragen do? IntegraGen SA is a French biotechnology company based in Evry. It was founded in 2000 and is one of the leading companies in developing commercial applications in genomics and biology. The business model of IntegraGen SA consists of providing solutions and services for the diagnosis and treatment of various diseases, such as cancer, neurodegenerative diseases, and other genetically related diseases. The company is divided into two main areas: Diagnostics and Genomics. The Diagnostics area offers a wide range of services to its customers, including an oncology platform for the diagnosis and prediction of cancer using exclusive biomarker sets. Other diagnostic tests are used for the identification of microorganisms in clinical samples and the detection of autoimmune diseases. In the Genomics area, the focus is on the development and sale of PCR kits for genotyping single nucleotide polymorphisms (SNPs) and analysis kits for RNA expression. These solutions allow for the identification and validation of genes in specific biological samples in a way that improves customers' understanding and enables accurate findings. IntegraGen SA is committed to continuously developing new tests and platforms to help its customers achieve more precise diagnoses and better therapies. One notable development of the company is the screening kit "Arisk," which is specifically designed for identifying genotypes that have an increased risk of colorectal cancer. The screening kit uses specific SNPs to ensure that doctors can identify patients who require increased monitoring or even prophylactic surgery. The use of genomics technology and biomarker-based diagnostics is a growing trend in medicine. IntegraGen SA plays a significant role in enabling the integration of genomics into clinical practice, ensuring the best possible diagnosis and treatment for patients. In summary, IntegraGen SA is an innovative biotechnology company dedicated to providing solutions for the diagnosis and prevention of diseases using various technologies. The company is constantly striving to develop new products and services to provide customers and partners with the best possible diagnostic and therapeutic support. Integragen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Integragen stock

Net Profit Margin of Integragen is -53.06 % in 2026.

Access this data via the Eulerpool API

Margins — Integragen

All Key Metrics — Integragen